David Zlotnick, MD
Interventional Cardiology · Buffalo, NYNPI 1366548364
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Angiodynamics, Inc. at 49.8% of the total. 2025 is the largest year on record at $91,928, 2.2 times the $42,263 reported in 2019. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 697 payments — averaging $529.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$184K
- Inari Medical, Inc.$76K
- Stryker$40K
- Abiomed$31K
- Abbott$22K
- AstraZeneca$12K
- plus $5K from 22 others
Across 237 payments — averaging $1888.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$250K
- Penumbra, Inc.$70K
- EKOS Corporation$45K
- Angiodynamics, Inc.$26K
- Boston Scientific$23K
- Philips North America LLC$13K
- plus $21K from 4 others
What the payments were for
- Consulting fees$211,59157%
- Speaking & faculty fees$79,23521%
- Grants$420%
- Travel & lodging$60,56816%
- Food & beverage$17,5865%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 162 | $183,684 |
| Inari Medical, Inc. | 103 | $75,579 |
| Stryker | 16 | $39,790 |
| Abiomed | 164 | $30,581 |
| Abbott | 48 | $22,143 |
| AstraZeneca | 19 | $12,314 |
| Boston Scientific | 61 | $1,520 |
| Edwards Lifesciences | 49 | $1,191 |
| Philips North America LLC | 6 | $505 |
| W. L. Gore & Associates, Inc. | 13 | $338 |
| Argon Medical Devices, Inc. | 1 | $200 |
| Novartis | 13 | $187 |
| Medtronic(2 entities) | 11 | $158 |
| Cardiovascular Systems Inc. | 5 | $137 |
| Janssen Scientific Affairs, LLC | 1 | $97 |
| Prodigy Surgical Distribution, Inc. | 1 | $84 |
| Amgen | 4 | $82 |
| Impulse Dynamics (USA) Inc. | 2 | $62 |
| Lexicon Pharmaceuticals, Inc. | 2 | $55 |
| Pfizer | 3 | $54 |
| Terumo Medical Corporation | 3 | $51 |
| Recor Medical Inc | 2 | $46 |
| Penumbra, Inc. | 3 | $42 |
| Cook Medical LLC | 1 | $42 |
| Getinge USA Sales, LLC | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AngioVac$113,258
- CT THROMBECTOMY SYSTEM KIT$99,306
- FLOWTRIEVER CATHETER, S$82,576
- AlphaVac$40,194
- Impella$28,862
- CLOTTRIEVER BOLD CATHETER$18,719
- BRILINTA$12,112
- AMPLATZER PICCOLO$6,550
- Xience V coronary stent system$6,038
- Dragonfly OCT$3,325
- FlowTriever$3,219
- ClotTriever$3,100
- DRAGONFLY OPSTAR$1,400
- OMNILINK ELITE$1,313
- HeartMate PHP$1,050
- ESPRIT$1,050
- Edwards SAPIEN 3 Transcatheter Heart Valve$613
- Omnilink Elite vascular stent system$500
- (5027) Intact Vascular Und$446
- Watchman$350
How this compares
$369,021 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cilostazol | 15 | $393 |
| Rosuvastatin Calcium | 28 | $311 |
| Metoprolol Succinate | 12 | $276 |
| Lisinopril | 21 | $269 |
| Amlodipine Besylate | 20 | $196 |
| Atorvastatin Calcium | 11 | $134 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Buffalo
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- David CohenRoslyn$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.